The board of NexPoint Capital Inc., a publicly registered non-traded business development company (BDC) focusing on healthcare, approved the suspension of the company’s monthly distribution. The suspension is for both cash distributions and those offered through NexPoint’s distribution reinvestment plan.
According to news reports, NexPoint Capital said the decision was made “to provide additional financial flexibility…and to maintain a conservative distribution policy during recent volatile market conditions.”
The board also approved a net asset value per share of $5.69, effective June 3, 2020, for the company’s common stock. The previous NAV per share was $5.25, which was effective April 29, 2020. NexPoint Capital investors originally purchased this investment at or around $10.00 per share. This represents a substantial loss to the individual investors. These products may have been misrepresented by the brokers or financial advisors to their clients, particularly those who have a low risk or retirement portfolio, as safe, secure, income-based investments which will pay distributions. When in fact, they are high-commissioned investments which can be risky and could cause retirees to lose their irreplaceable retirement funds.
By suspending the monthly distributions to the shareholders, NexPoint Capital shocked their investors who originally purchased the shares for the distributions. The distributions were one of the top selling points for the investment recommended by brokers/dealers.
If your broker/dealer recommended that you invest in NexPoint Capital and they may have told you it was a secure, safe investment with a reliable distribution income stream and you’ve now suffered financial losses, contact Soreide Law Group and speak to an experienced securities lawyer at no cost to you regarding the possible recovery of your financial losses through a FINRA arbitration at: 888-760-6552.
Soreide Law Group represents our clients nationally before FINRA. We operate on a contingency fee basis—no fee to you if no recovery.
Soreide Law Group is investigating potential investor claims involving Cove Capital 1031 Delaware Statutory Trust (DST) investments and whether brokers improperly recommended these specific tax-deferred real estate offerings. Cove Capital 1031 DSTs are structured investments that allow investors to reinvest proceeds from the sale of real estate into fractional interests in institutional-grade properties while deferring […]
Investors might have sustained losses due to securities broker Marc Charles Koch [CRD: 4978078, New York, New York], given the publicly available information found on Financial Industry Regulatory Authority (FINRA) BrokerCheck. Koch worked for Morgan Stanley from March 30, 2023, to the present, First Republic Investment Management Inc. from November 7, 2022, to April 25, […]
Investors potentially incurred losses because of securities broker Stephen Charles Newell Hlibok (also known as Stephen Hlibok and Steve Hlibok) [CRD: 1728900, Columbia, Maryland], according to disclosures on Financial Industry Regulatory Authority (FINRA) BrokerCheck. Hlibok worked for Merrill Lynch Pierce Fenner Smith Incorporated from September 25, 1987, to the present as a broker, and from […]
Phone:
Fax: 1-954-760-6553
Email: info@securitieslawyer.com